FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895815892> ?p ?o ?g. }

• W2895815892 endingPage "23" @default.
• W2895815892 startingPage "14" @default.
• W2895815892 abstract "This study investigated treatment adherence among people with recent injecting drug use in a study of sofosbuvir/velpatasvir therapy for HCV infection. SIMPLIFY is an international open-label, single-arm multicentre study that recruited participants with recent injecting drug use (previous six months) and chronic HCV genotype (G) 1–6 infection between March and October 2016 in seven countries (19 sites). Participants received sofosbuvir/velpatasvir once-daily for 12 weeks administered in a one-week electronic blister pack (records the time and date of each dose) for 12 weeks. We evaluated non-adherence (<90% adherent) as measured by electronic blister-pack assessed using logistic regression and generalised estimating equations (continuous) with detailed analyses of dosing dynamics. Among 103 participants, 97% (n = 100) completed treatment. Median adherence to therapy was 94%. Overall, 32% (n = 33) were considered non-adherent (<90% adherence). Adherence significantly decreased over the course of therapy. Recent stimulant injecting (cocaine and/or amphetamines) at treatment initiation and during treatment was independently associated with non-adherence. Inconsistent dose timing (standard deviation of daily dose timing of ≥240 min) was also independently associated with non-adherence to therapy. Factors associated with inconsistent dose timing included lower levels of education and recent stimulant injecting. SVR was similar among adherent and non-adherent populations (94% vs. 94%, P = 0.944). This study demonstrated high adherence to once-daily sofosbuvir/velpatasvir therapy among a population of people with recent injecting drug use. Recent stimulant injecting prior to and during DAA therapy and inconsistent dose-timing during treatment was associated with non-adherence. However, there was no impact of non-adherence on response to therapy, suggesting that adherence is not a significant barrier to successful DAA therapy in people with recent injecting drug use." @default.
• W2895815892 created "2018-10-26" @default.
• W2895815892 creator A5004579061 @default.
• W2895815892 creator A5008990660 @default.
• W2895815892 creator A5009499168 @default.
• W2895815892 creator A5009631266 @default.
• W2895815892 creator A5013176250 @default.
• W2895815892 creator A5018402214 @default.
• W2895815892 creator A5020475843 @default.
• W2895815892 creator A5027714342 @default.
• W2895815892 creator A5028544789 @default.
• W2895815892 creator A5029267264 @default.
• W2895815892 creator A5030105607 @default.
• W2895815892 creator A5033648105 @default.
• W2895815892 creator A5033798070 @default.
• W2895815892 creator A5037354571 @default.
• W2895815892 creator A5041369213 @default.
• W2895815892 creator A5041740623 @default.
• W2895815892 creator A5045529959 @default.
• W2895815892 creator A5049864482 @default.
• W2895815892 creator A5052909853 @default.
• W2895815892 creator A5054107081 @default.
• W2895815892 creator A5061560140 @default.
• W2895815892 creator A5062480277 @default.
• W2895815892 creator A5067193474 @default.
• W2895815892 creator A5073065098 @default.
• W2895815892 creator A5083442088 @default.
• W2895815892 creator A5087723811 @default.
• W2895815892 creator A5088842832 @default.
• W2895815892 creator A5025235180 @default.
• W2895815892 date "2018-12-01" @default.
• W2895815892 modified "2023-09-26" @default.
• W2895815892 title "Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study" @default.
• W2895815892 cites W1604838036 @default.
• W2895815892 cites W1903580466 @default.
• W2895815892 cites W1985686008 @default.
• W2895815892 cites W2001458978 @default.
• W2895815892 cites W2006747389 @default.
• W2895815892 cites W2008562148 @default.
• W2895815892 cites W2022053192 @default.
• W2895815892 cites W2033605805 @default.
• W2895815892 cites W2045555817 @default.
• W2895815892 cites W2083304527 @default.
• W2895815892 cites W2126529103 @default.
• W2895815892 cites W2135630746 @default.
• W2895815892 cites W2152508795 @default.
• W2895815892 cites W2288196111 @default.
• W2895815892 cites W2514263904 @default.
• W2895815892 cites W2518041763 @default.
• W2895815892 cites W2518485884 @default.
• W2895815892 cites W2540946530 @default.
• W2895815892 cites W2570363312 @default.
• W2895815892 cites W2591108500 @default.
• W2895815892 cites W2605116305 @default.
• W2895815892 cites W2605284316 @default.
• W2895815892 cites W2607269243 @default.
• W2895815892 cites W2625414995 @default.
• W2895815892 cites W2626989754 @default.
• W2895815892 cites W2657409977 @default.
• W2895815892 cites W2750028296 @default.
• W2895815892 doi "https://doi.org/10.1016/j.drugpo.2018.08.013" @default.
• W2895815892 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30352330" @default.
• W2895815892 hasPublicationYear "2018" @default.
• W2895815892 type Work @default.
• W2895815892 sameAs 2895815892 @default.
• W2895815892 citedByCount "51" @default.
• W2895815892 countsByYear W28958158922019 @default.
• W2895815892 countsByYear W28958158922020 @default.
• W2895815892 countsByYear W28958158922021 @default.
• W2895815892 countsByYear W28958158922022 @default.
• W2895815892 countsByYear W28958158922023 @default.
• W2895815892 crossrefType "journal-article" @default.
• W2895815892 hasAuthorship W2895815892A5004579061 @default.
• W2895815892 hasAuthorship W2895815892A5008990660 @default.
• W2895815892 hasAuthorship W2895815892A5009499168 @default.
• W2895815892 hasAuthorship W2895815892A5009631266 @default.
• W2895815892 hasAuthorship W2895815892A5013176250 @default.
• W2895815892 hasAuthorship W2895815892A5018402214 @default.
• W2895815892 hasAuthorship W2895815892A5020475843 @default.
• W2895815892 hasAuthorship W2895815892A5025235180 @default.
• W2895815892 hasAuthorship W2895815892A5027714342 @default.
• W2895815892 hasAuthorship W2895815892A5028544789 @default.
• W2895815892 hasAuthorship W2895815892A5029267264 @default.
• W2895815892 hasAuthorship W2895815892A5030105607 @default.
• W2895815892 hasAuthorship W2895815892A5033648105 @default.
• W2895815892 hasAuthorship W2895815892A5033798070 @default.
• W2895815892 hasAuthorship W2895815892A5037354571 @default.
• W2895815892 hasAuthorship W2895815892A5041369213 @default.
• W2895815892 hasAuthorship W2895815892A5041740623 @default.
• W2895815892 hasAuthorship W2895815892A5045529959 @default.
• W2895815892 hasAuthorship W2895815892A5049864482 @default.
• W2895815892 hasAuthorship W2895815892A5052909853 @default.
• W2895815892 hasAuthorship W2895815892A5054107081 @default.
• W2895815892 hasAuthorship W2895815892A5061560140 @default.
• W2895815892 hasAuthorship W2895815892A5062480277 @default.
• W2895815892 hasAuthorship W2895815892A5067193474 @default.
• W2895815892 hasAuthorship W2895815892A5073065098 @default.
• W2895815892 hasAuthorship W2895815892A5083442088 @default.

• next